BR112018007625A2 - composição antibacteriana combinada e regime antibacteriano de curto prazo - Google Patents
composição antibacteriana combinada e regime antibacteriano de curto prazoInfo
- Publication number
- BR112018007625A2 BR112018007625A2 BR112018007625A BR112018007625A BR112018007625A2 BR 112018007625 A2 BR112018007625 A2 BR 112018007625A2 BR 112018007625 A BR112018007625 A BR 112018007625A BR 112018007625 A BR112018007625 A BR 112018007625A BR 112018007625 A2 BR112018007625 A2 BR 112018007625A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibacterial
- regimen
- short term
- combined
- composition
- Prior art date
Links
- 230000000844 anti-bacterial effect Effects 0.000 title 2
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229960000508 bedaquiline Drugs 0.000 abstract 1
- QUIJNHUBAXPXFS-XLJNKUFUSA-N bedaquiline Chemical compound C1([C@H](C2=CC3=CC(Br)=CC=C3N=C2OC)[C@@](O)(CCN(C)C)C=2C3=CC=CC=C3C=CC=2)=CC=CC=C1 QUIJNHUBAXPXFS-XLJNKUFUSA-N 0.000 abstract 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 abstract 1
- 229960003907 linezolid Drugs 0.000 abstract 1
- 229960005206 pyrazinamide Drugs 0.000 abstract 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 201000008827 tuberculosis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562241280P | 2015-10-14 | 2015-10-14 | |
| PCT/US2016/055414 WO2017066053A1 (en) | 2015-10-14 | 2016-10-05 | Combination antibacterial composition and short-course antibacterial regimen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018007625A2 true BR112018007625A2 (pt) | 2018-10-30 |
Family
ID=58518568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018007625A BR112018007625A2 (pt) | 2015-10-14 | 2016-10-05 | composição antibacteriana combinada e regime antibacteriano de curto prazo |
Country Status (14)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108495631A (zh) * | 2015-10-14 | 2018-09-04 | 结核病药物开发全球联盟公司 | 联合抗菌组合物以及短疗程抗菌方案 |
| CN109387594B (zh) * | 2017-08-08 | 2021-01-19 | 武汉武药科技有限公司 | 一种分离和分析贝达喹啉光学异构体的方法 |
| BR112022000899A2 (pt) * | 2019-07-19 | 2022-03-29 | The Global Alliance For Tb Drug Dev Inc | Composições de pretomanida |
| WO2021257461A1 (en) * | 2020-06-15 | 2021-12-23 | Mylan Laboratories Limited | Combination antibacterial composition and method for antibacterial therapy |
| GB202009684D0 (en) * | 2020-06-26 | 2020-08-12 | Viiv Healthcare Co | Formulations |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7889101B2 (en) * | 2008-04-14 | 2011-02-15 | Alpine Electronics, Inc | Method and apparatus for generating location based reminder message for navigation system |
| CA2735229C (en) * | 2008-09-03 | 2014-01-28 | Pfizer Inc. | Combination therapy for tuberculosis |
| WO2011139832A2 (en) * | 2010-04-28 | 2011-11-10 | Rib-X Pharmaceuticals, Inc. | Method for treating mycobacterial infections |
| CN108495631A (zh) * | 2015-10-14 | 2018-09-04 | 结核病药物开发全球联盟公司 | 联合抗菌组合物以及短疗程抗菌方案 |
-
2016
- 2016-10-05 CN CN201680073150.2A patent/CN108495631A/zh active Pending
- 2016-10-05 KR KR1020187013661A patent/KR20180063318A/ko active IP Right Grant
- 2016-10-05 ES ES16855973T patent/ES2972618T3/es active Active
- 2016-10-05 HR HRP20240309TT patent/HRP20240309T1/hr unknown
- 2016-10-05 BR BR112018007625A patent/BR112018007625A2/pt not_active Application Discontinuation
- 2016-10-05 JP JP2018518950A patent/JP6845233B2/ja active Active
- 2016-10-05 AU AU2016338637A patent/AU2016338637A1/en not_active Abandoned
- 2016-10-05 EP EP23214018.6A patent/EP4324824A3/en active Pending
- 2016-10-05 CN CN202210425060.2A patent/CN114796231A/zh active Pending
- 2016-10-05 WO PCT/US2016/055414 patent/WO2017066053A1/en active Application Filing
- 2016-10-05 EP EP16855973.0A patent/EP3362068B1/en active Active
- 2016-10-05 CA CA3001309A patent/CA3001309C/en active Active
- 2016-10-05 US US15/765,310 patent/US20180280401A1/en active Pending
- 2016-10-05 EA EA201890614A patent/EA201890614A1/ru unknown
-
2018
- 2018-04-05 ZA ZA2018/02236A patent/ZA201802236B/en unknown
- 2018-10-23 HK HK18113586.3A patent/HK1254620A1/zh unknown
-
2020
- 2020-04-09 US US16/843,946 patent/US20200237770A1/en not_active Abandoned
- 2020-11-27 JP JP2020196684A patent/JP7221922B2/ja active Active
-
2021
- 2021-10-28 AU AU2021258039A patent/AU2021258039B2/en active Active
-
2022
- 2022-04-07 JP JP2022063917A patent/JP2022082753A/ja active Pending
-
2023
- 2023-09-06 US US18/242,560 patent/US20230414625A1/en active Pending
-
2024
- 2024-03-07 JP JP2024034841A patent/JP2024053045A/ja active Pending
- 2024-05-07 AU AU2024203012A patent/AU2024203012A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017066053A1 (en) | 2017-04-20 |
| AU2021258039A1 (en) | 2021-11-25 |
| AU2021258039B2 (en) | 2024-02-08 |
| JP2024053045A (ja) | 2024-04-12 |
| EP4324824A2 (en) | 2024-02-21 |
| JP2022082753A (ja) | 2022-06-02 |
| US20230414625A1 (en) | 2023-12-28 |
| CA3001309C (en) | 2023-12-19 |
| JP6845233B2 (ja) | 2021-03-17 |
| AU2016338637A1 (en) | 2018-04-26 |
| JP2018530578A (ja) | 2018-10-18 |
| US20180280401A1 (en) | 2018-10-04 |
| EP4324824A3 (en) | 2024-05-08 |
| KR20180063318A (ko) | 2018-06-11 |
| HK1254620A1 (zh) | 2019-07-26 |
| ZA201802236B (en) | 2022-07-27 |
| US20200237770A1 (en) | 2020-07-30 |
| EP3362068A1 (en) | 2018-08-22 |
| CN114796231A (zh) | 2022-07-29 |
| AU2024203012A1 (en) | 2024-05-23 |
| HRP20240309T1 (hr) | 2024-05-10 |
| CN108495631A (zh) | 2018-09-04 |
| JP2021038257A (ja) | 2021-03-11 |
| EA201890614A1 (ru) | 2019-02-28 |
| EP3362068A4 (en) | 2019-06-19 |
| EP3362068C0 (en) | 2023-12-20 |
| EP3362068B1 (en) | 2023-12-20 |
| CA3001309A1 (en) | 2017-04-20 |
| ES2972618T3 (es) | 2024-06-13 |
| JP7221922B2 (ja) | 2023-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018007625A2 (pt) | composição antibacteriana combinada e regime antibacteriano de curto prazo | |
| PH12017502297A1 (en) | Antibacterial compounds | |
| CY1119566T1 (el) | Αντιϊικες ενωσεις rsv | |
| CL2016000556A1 (es) | Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso. | |
| BR112018004532A2 (pt) | uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos | |
| BR112017009497A2 (pt) | polinucleotídeos de aadc para o tratamento da doença de parkinson | |
| BR112016014410A2 (pt) | terapia de combinação com vacina de neoantígeno | |
| BR112019002538A2 (pt) | uso de uma composição farmacêutica compreendendo um modulador alostérico, uso de uma composição farmacêutica compreendendo garboxadol ou um sal farmaceuticamente aceitável do mesmo, e composição farmacêutica para a administração parenteral | |
| BR112017007072A2 (pt) | compostos de triazolopiridina e métodos para o tratamento de fibrose cística | |
| BR112017006940A2 (pt) | triazolopirazinonas como inibidores de pde1 | |
| EA201691481A1 (ru) | ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ | |
| CO2017010399A2 (es) | Imidazopirazinonas como inhibidores de pde1 | |
| ECSP16008797A (es) | Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos | |
| EA201792566A1 (ru) | Замещенные фенилоксазолидиноны для антимикробной терапии | |
| BR112017005209A2 (pt) | compostos moduladores de pirrolopiridina substituída por metila e trifluorometila de rorc2 e seu uso | |
| CY1122403T1 (el) | Μορφες δοσολογιας και θεραπευτικες χρησεις της l-4-χλωροκυνουρενινης | |
| BR112016013116A2 (pt) | Inibidores de trifluorometil pirazolil guanidina f1f0-atpase, seus usos, e composições farmacêuticas | |
| BR112019005040A2 (pt) | aplicação de pridopidina para tratamento de síndrome de rett | |
| BR112017019337A2 (pt) | tratamento de dor | |
| BR112017024039B8 (pt) | Piroglutamato de vortioxetina, composições farmacêuticas e gel compreendendo o mesmo, método para preparar um gel, e usos do piroglutamato de vortioxetina para fabricação de um medicamento ou gel | |
| MX2015010296A (es) | Tratamiento de formas progresivas de esclerosis multiple con laquinimod. | |
| DOP2018000049A (es) | Compuestos para uso en aplicaciones antibacterianas | |
| BR112015024703A2 (pt) | formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose | |
| CY1124229T1 (el) | Συνδυασμος τραζοδονης και γκαμπαπεντινης για την αντιμετωπιση του πονου | |
| BR112017011777A2 (pt) | antagonista de a2a de dosagem baixa para o tratamento de tdah e doença de parkinson |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |